FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. - Wikidata - wikimedia - TriplyDB

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

http://www.wikidata.org/entity/Q34035797

about

Pathophysiological roles of FGF signaling in the heart Endocrine crosstalk between muscle and bone Fibroblast Growth Factor-23-A Potential Uremic Toxin FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.The use of fibroblast growth factor 23 testing in patients with kidney disease.Fibroblast growth factor-23 and cardiac structure and function.Fibroblast growth factor 23: a novel key to find hidden substrates of atrial fibrillation?Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.Fibroblast growth factor 23 in acute kidney injury.Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease The Fibroblast Growth Factor signaling pathway Pathogenesis of arrhythmias in a model of CKD.Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients Fibroblast growth factor 23 and risk of incident stroke in community-living adults FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells.Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB.Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets.The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.Inflammation regulates fibroblast growth factor 23 production.The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know.Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages.A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes.What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.Novel metabolic biomarkers of cardiovascular disease.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.Elevation of plasma oncostatin M in heart failure.Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.Ironing out the cross talk between FGF23 and inflammation.Extrarenal effects of FGF23.Cardiac actions of fibroblast growth factor 23.Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury.The Role of the Osteocyte in Bone and Nonbone Disease.Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction.Isolation and physiological analysis of mouse cardiomyocytes.Fibroblast growth factor 23 and heart failure: the plot thickens.

P2860

Q26853186-D01920C8-F52A-4918-A85B-E06B96F1ABEA Q27008987-4B1F7519-DA43-4BD0-B0E3-66ACEBB5F58B Q28075648-08DC25FE-D977-49ED-BF06-7CA08F12789E Q33694566-5F3C5E4B-380B-4955-A83C-7F901AE998D4 Q33835743-4EC31009-5DAC-4EA2-B802-1A73E283FE74 Q34039877-D050981B-22F1-47FB-8394-68CD3FA219F3 Q34061048-37BA5396-BC08-4941-87F0-D2E80B04C6C0 Q34069793-B5F99357-D4B3-4429-B8F4-A237045402A4 Q34130840-AD0C505A-A0A5-4A58-A186-AC2C6C3B45F0 Q34280125-A58DBF79-897F-4B8F-8FC9-D051105298BE Q34421217-394E2C3E-88BA-486A-88A5-B3F76C8CF03F Q34467171-B81B5761-93E1-4C51-AFAB-5C1258C09BAC Q34568828-8B70C206-0D61-43D9-B455-2C0140312F15 Q34988878-D78419EF-2339-484A-99D7-FB988223B7F7 Q35019943-8FD7F819-F1F0-43E9-8C12-EB9774CA9706 Q35190689-75080A42-7755-4AB3-B29C-D65EFDCA7916 Q35527857-D500AC4F-FAE2-4887-9C73-0BB3EFE7025E Q35997370-F6DE96E2-544E-4F2F-901A-2C80BD913084 Q36863458-456C999F-663D-4C3E-9F7C-0F1A8418CA22 Q36899883-6AF92B3E-D427-42E4-884F-F15AC1098D5E Q36963471-6AED991A-521A-4DBE-BE15-4D7D370A83F4 Q37243107-4A15AE78-731F-4948-9402-CB4079C6CA7F Q37296494-6E6F5DAA-9251-4B06-82A4-FECDDC16F425 Q37365288-442E72AE-B4F7-463C-A132-400F464B126F Q37614180-D73DE94E-2C38-4107-8D93-BE2139FED228 Q37688345-25EBF164-E650-4CB6-8969-6A25492C0F1D Q38150052-D8B3AF34-8E4A-431E-8E9D-105B4C338CAE Q38200883-E7F5F918-FB3C-499A-B891-5F49815C2E41 Q38245327-32BFA767-2AB2-49AC-904E-27D95EB5D068 Q38633258-A369CDDB-CC6F-4CF3-93A5-BD9CE60B837D Q38674256-90E2C318-E4DA-4BDA-A3E6-F609019D9A29 Q38878795-9D03BA86-F61D-452F-BA81-7F252954AF5B Q38942965-C2E07172-F5B0-45F2-A64C-C184ADE11680 Q38972469-100EB633-C20E-4650-8A61-38CA76AC2C12 Q38977291-7B8B02EC-6ABF-44BE-8E2D-FA2E92AC224C Q39003429-A2A1B6F7-4088-432D-899C-A3F59EA74FDF Q39107516-EEF5EF4B-1D3F-4F05-B65D-5540E84557C0 Q39122744-D563E520-ADD9-4825-B37E-F763851EE1CD Q40044628-2856C9F0-D0BB-4107-AEF0-A2704DD807EC Q41091515-435C2483-DB71-4A06-B138-6E836289F4EE

P2860

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

http://www.wikidata.org/entity/Q34035797

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@ast

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@en

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@nl

type

label

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@ast

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@en

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@nl

prefLabel

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@ast

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@en

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@nl

P1433

Q34035797-F65B5646-6BD4-4938-81A7-F24F14D2E1C7

P1476

Q34035797-C4D41476-60C8-40DB-968D-881D08D60C87

P2093

Q34035797-05224833-DC99-40D6-B872-7228A975EC67

Q34035797-1CF43624-0003-4277-AFC5-663AB2AA497B

Q34035797-3B4B19FB-8B8C-411C-B9D5-2281738A718B

Q34035797-5FF44CE8-D13D-4A99-89A2-19EE306212B1

Q34035797-780FE68F-D372-42A5-B2D5-C6FBB7D3B09B

Q34035797-795FBFEA-6BB1-478D-B81E-12D1F496FCBE

Q34035797-86283CD9-01AB-4E03-8847-7EB76AB1194B

Q34035797-8FEF144B-14F3-4972-9BD7-1FBF20A89672

Q34035797-96E33E91-AEB6-4607-A707-7FD0C726E2C5

Q34035797-AB93EFFF-1A5A-4D23-8532-87FCBD7D1FC8

P2860

Q34035797-07B8A636-5170-4143-9E80-F4FF9AD4710B

Q34035797-08991293-213A-4BFD-9998-42756E1BF153

Q34035797-09A5C647-51D5-4BE9-B18C-4FD41A329E0A

Q34035797-0BBEBF13-5466-4C36-B2D6-221871999B11

Q34035797-0C2B8E14-3D83-4A7A-B70A-B686946CCD9C

Q34035797-0D1032B1-B541-43B1-B473-AEAB2C46478E

Q34035797-110F7B12-864C-4EFA-B2E8-8DB924B160DF

Q34035797-117F3CFE-E189-4EE1-9858-F22250D6EB2C

Q34035797-243DAD19-A338-451F-A9F1-2D5269A32F1F

Q34035797-2A8AF1B6-A1FF-419F-A69A-FD59710E589D

P304

Q34035797-88B6A647-C78D-4BE4-BADD-8D523579AEC8

P31

Q34035797-4484B5B3-88E1-4017-B77C-4400F4151395

P356

Q34035797-A9663DB5-0C18-44C5-9947-96C17CE70724

P433

Q34035797-56B5DEB0-D51D-4BA5-A8D6-64D93F2ACBAC

P478

Q34035797-5FC9C54A-DECD-43C1-9CA6-8B519B8E8320

P577

Q34035797-9B379A2C-ED84-4554-894D-3A3C5C499755

P5875

Q34035797-887E1EF4-7380-41E6-BA25-02BA9F6C876C

P698

Q34035797-0C1C4D9A-C6C2-4508-9E6E-95259A6E2536

P932

Q34035797-78AD4CB1-CE2C-4ECB-97BB-C4193F30460F

P356

AJPENDO.00596.2012

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

FGF23 is a novel regulator of ...... dition to cardiac hypertrophy.

@en

P2093

Brandon W Carney

http://www.w3.org/2001/XMLSchema#string

Buddhadeb Dawn

http://www.w3.org/2001/XMLSchema#string

Chad D Touchberry

http://www.w3.org/2001/XMLSchema#string

Jaimee E Mannix

http://www.w3.org/2001/XMLSchema#string

Jason R Stubbs

http://www.w3.org/2001/XMLSchema#string

Lori A Wetmore

http://www.w3.org/2001/XMLSchema#string

Lynda F Bonewald

http://www.w3.org/2001/XMLSchema#string

Magdy Girgis

http://www.w3.org/2001/XMLSchema#string

Michael J Wacker

http://www.w3.org/2001/XMLSchema#string

Robert J Vincent

http://www.w3.org/2001/XMLSchema#string

P2860

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

Klotho converts canonical FGF receptor into a specific receptor for FGF23

The parathyroid is a target organ for FGF23 in rats

HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte

In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.

P304

E863-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00596.2012

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235740919

http://www.w3.org/2001/XMLSchema#string

P698

23443925

http://www.w3.org/2001/XMLSchema#string

P932

3625783

http://www.w3.org/2001/XMLSchema#string